BIOMERICA INC (BMRA) is a publicly traded Healthcare sector company. As of May 21, 2026, BMRA trades at $2.35 with a market cap of $6.95M and a P/E ratio of -0.93. BMRA moved +0.00% today. Year to date, BMRA is -9.62%; over the trailing twelve months it is -35.44%. Its 52-week range spans $1.87 to $10.16. Rallies surfaces BMRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in BMRA news today?
Biomerica to Present Real-World inFoods IBS Study Showing 59.6% Pain Reduction: Biomerica’s real-world study on its inFoods IBS guided diagnostic therapy has been accepted for presentation at Digestive Disease Week 2026 in Chicago. The upcoming poster will present data showing 59.6% of treated patients achieved FDA abdominal pain reduction endpoints versus 42.1% in controls.
Irani Zackary S. bought 200 (~$310) on May 25, 2023.
Irani Zackary S. bought 500 (~$805) on May 24, 2023.
Irani Zackary S. bought 1.70K (~$1.99K) on May 12, 2023.
BMRA Analyst Consensus
BMRA analyst coverage data. Average price target: $0.00.
Common questions about BMRA
What changed in BMRA news today?
Biomerica to Present Real-World inFoods IBS Study Showing 59.6% Pain Reduction: Biomerica’s real-world study on its inFoods IBS guided diagnostic therapy has been accepted for presentation at Digestive Disease Week 2026 in Chicago. The upcoming poster will present data showing 59.6% of treated patients achieved FDA abdominal pain reduction endpoints versus 42.1% in controls.
Does Rallies summarize BMRA news?
Yes. Rallies summarizes BMRA news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is BMRA research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BMRA. It does not provide personalized investment advice.
